Upregulation of ligand, receptor system, and amidating activity of adrenomedullin in left ventricular hypertrophy of severely hypertensive rats: Effects of angiotensin-converting enzyme inhibitors and diuretic

Journal of Hypertension

Volumn 21, Issue 6, 2003, Pages 1171-1181

  Wang, Xin ^a   Nishikimi, Toshio ^a   Akimoto, Kazumi ^a   Tadokoro, Kazuyoshi ^a   Mori, Yosuke ^a   Minamino, Naoto ^b  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Adrenomedullin; Hypertension; Left ventricular hypertrophy

Indexed keywords

ADRENOMEDULLIN; ADRENOMEDULLIN RECEPTOR; ATRIAL NATRIURETIC FACTOR; CALCITONIN RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCINE DERIVATIVE; LIGAND; MESSENGER RNA; PROADRENOMEDULLIN; RECEPTOR ACTIVITY MODIFYING PROTEIN; TRICHLORMETHIAZIDE;

AMIDATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; GENE EXPRESSION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERTENSION; IMMUNORADIOMETRIC ASSAY; MALE; MEASUREMENT; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION;

EID: 0037864312     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200306000-00018     Document Type: Article

References (43)

1. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192:553-560.
2. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000; 21:138-167.
3. Nishikimi T, Horio T, Yoshihara F, Nagaya N, Matsuo H, Kangawa K. Effect of adrenomedullin on cAMP and cGMP levels in rat cardiac myocytes and nonmyocytes. Eur J Pharm 1998; 353:337-344.
4. Szokodi I, Kinnunen P, Tavi P, Weckstrom M, Toth M, Ruskoaho H. Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation 1998; 97:1062-1070.
5. Sakata J, Shimokubo T, Kitamura K, Nishizono M, Ichiki Y, Kangawa K, et al. Distribution and characterization of immunoreactive rat adrenomedullin in tissue and plasma. FEBS Lett 1994; 352:105-108.
6. Nishikimi T, Saito Y, Kitamura K, Ishimitsu T, Eto T, Kangawa K, et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 1995; 26:1424-1431.
7. Kobayashi K, Kitamura K, Etoh T, Nagatomo Y, Takenaga M, Ishikawa T, et al. Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J 1996; 131:994-998.
8. Asakawa H, Nishikimi T, Suzuki T, Hara S, Tsubokou Y, Yagi H, et al. Elevation of two molecular forms of adrenomedullin in plasma and urine in patients with acute myocardial infarction treated with early coronary angioplasty. Clin Sci 2001; 100:117-126.
9. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97:1921-1929.
10. Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994; 94:2158-2161.
11. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport, and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393:333-339.
12. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharm Rev 2002; 54:233-246.
13. Totsune K, Takahashi K, Mackenzie HS, Murakami O, Arihara Z, Sone M, et al. Increased gene expression of adrenomedullin and adrenomedullin-receptor complexes, receptor-activity modifying protein (RAMP) 2 and calcitonin-receptor-like receptor (CRLR) in the hearts of rats with congestive heart failure. Clin Sci 2000; 99:541-546.
14. Kitamura K, Kato J, Kawamoto M, Tanaka M, Chino N, Kangawa K, et al. The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in Human plasma. Biochem Biophys Res Commun 1998; 244:551-555.
15. Nishikimi T, Matsuoka H, Shimada K, Matsuo H, Kangawa K. Production and clearance sites of two molecular forms of adrenomedullin in human plasma. Am J Hypertens 2000; 13:1032-1034.
16. Yamori Y, Nara Y, Mizushima S, Murakami S, Ikeda K, Sawamura M, et al. Gene-environment interaction in hypertension, stroke and atherosclerosis in experimental models and supportive findings from a world-wide cross-sectional epidemiological survey: a WHO-cardiac study. Clin Exp Pharm Physiol Suppl 1992; 20:43-52.
17. Nagaya N, Nishikimi T, Yoshihara F, Horio T, Morimoto A, Kangawa K. Cardiac adrenomedullin gene expression and peptide accumulation after acute myocardial infarction in rats. Am J Physiol Regul Integrative Comp Physiol 2000; 278:R1019-R1026.
18. Nishikimi T, Yoshihara F, Kanazawa A, Okano I, Horio T, Nagaya N, et al. Role of increased circulating and renal adrenomedullin in rats with malignant hypertension. Am J Physiol Regul Integr Comp Physiol 2001; 281:R2079-2087.
19. Nishikimi T, Mori Y, Kobayashi N, Tadokoro K, Wang X, Akimoto K, et al. Renoprotective effect of chronic adrenomedullin infusion in Dahl salt-sensitive rats. Hypertension 2002; 39:1077-1082.
20. Morimoto A, Nishikimi T, Yoshihara F, Horio T, Nagaya N, Matsuo H, et al. Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats. Hypertension 1999; 33:1146-1152.
21. Nishikimi T, Horio T, Sasaki T, Yoshihara F, Takishita S, Miyata A, et al. Cardiac production and secretion of adrenomedullin are increased in heart failure. Hypertension 1997; 30:1369-1375.
22. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, et al. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 2000; 279:H3031-H3039.
23. Yanagita T, Yamamoto R, Sugano T, Kobayashi H, Uezono Y, Yokoo H, et al. Adrenomedullin inhibits spontaneous and bradykinin-induced but not oxytocin- or prostaglandin F(2alpha)-induced periodic contraction of rat uterus. Br J Pharm 2000; 130:1727-1730.
24. Nishikimi T, Tadokoro K, Wang X, Mori Y, Asakawa H, Akimoto K, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin. Eur J Pharm 2002; 453:175-181.
25. Nishikimi T, Horio T, Kohmoto Y, Yoshihara F, Nagaya N, Inenaga T, et al. Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. J Hypertens 2001; 19:765-773.
26. Hirayama N, Kitamura K, Imamura T, Kato J, Koiwaya Y, Tsuji T, et al. Molecular forms of circulating adrenomedullin in patients with congestive heart failure. J Endocrinol 1999; 160:297-303.
27. Nishikimi T, Nagata S, Sasaki T, Yoshihara F, Nagaya N, Horio T, et al. The active molecular form of plasma adrenomedullin is extracted in the pulmonary circulation in patients with mitral stenosis: possible role of adrenomedullin in pulmonary hypertension. Clin Sci 2001; 100:61-66.
28. Hirano S, Ishiyama Y, Matsuo T, Imamura T, Sakata J, Kitamura K, et al. Decrease in circulating and urine adrenomedullin concentrations in stroke-prone spontaneously hypertensive rats. Hypertens Res 1998; 21:23-28.
29. Ishiyama Y, Kitamura K, Kato J, Sakata J, Kangawa K, Eto T. Changes in cardiac adrenomedullin concentration in renovascular hypertensive rats. Hypertens Res 1997; 20:113-117.
30. Shimokubo T, Sakata J, Kitamura K, Kangawa K, Matsuo H. Eto T. Adrenomedullin: changes in circulating and cardiac tissue concentration in Dahl salt-sensitive rats on a high-salt diet. Clin Exp Hypertens 1996; 18:949-961.
31. Maltese JY, Oyarce AM, Eipper BA. Prevalence and turnover of peptidylglycine alpha-amidating monooxygenase mRNA in atrial cardiomyocytes. J Mol Cell Cardiol 1996; 28:155-163.
32. Oie E, Vinge LE, Yndestad A, Sandberg C, Grogaard HK, Attramadal H. Induction of a myocardial adrenomedullin signaling system during ischemic heart failure in rats. Circulation 2000; 101:415-422.
33. Hagner S, Stahl U, Knoblauch B, McGregor GP, Lang RE. Calcitonin receptor-like receptor: identification and distribution in human peripheral tissues. Cell Tissue Res 2002; 310:41-50.
34. Autelitano DJ, Ridings R. Adrenomedullin signalling in cardiomyocytes is dependent upon CRLR and RAMP2 expression. Peptides 2001; 22:1851-1857.
35. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K. Effects of adrenomedullin on cultured rat cardiac myocytes and fibroblasts. Eur J Pharm 1999; 382:1-9.
36. Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, et al. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension 1998; 31:505-510.
37. Tsuruda T, Kato J, Kitamura K, Imamura T, Koiwaya Y, Kangawa K, et al. Enhanced adrenomedullin production by mechanical stretching in cultured rat cardiomyocytes. Hypertension 2000; 35:1210-1214.
38. Tomoda Y, Kikumoto K, Isumi Y, Katafuchi T, Tanaka A, Kangawa K, et al. Cardiac fibroblasts are major production and target cells of adrenomedullin in the heart in vitro. Cardiovasc Res 2001; 49:721-730.
39. Zhang JJ, Yoshida H, Chao L, Chao J. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive Dahl salt-sensitive rats. Hum Gene Ther 2000; 11:1817-1827.
40. Dobrzynski E, Wang C, Chao J, Chao L. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 2000; 36:995-1001.
41. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000; 35:19-24.
42. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, Smithies O, et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 2001; 107:975-984.
43. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci USA 2001; 98:2703-2706.